[go: up one dir, main page]

AR021922A1 - Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol. - Google Patents

Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.

Info

Publication number
AR021922A1
AR021922A1 ARP990106573A ARP990106573A AR021922A1 AR 021922 A1 AR021922 A1 AR 021922A1 AR P990106573 A ARP990106573 A AR P990106573A AR P990106573 A ARP990106573 A AR P990106573A AR 021922 A1 AR021922 A1 AR 021922A1
Authority
AR
Argentina
Prior art keywords
formoterol
fluoroalcans
budesonido
pharmaceutical formulations
aerosol containing
Prior art date
Application number
ARP990106573A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22802357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR021922(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of AR021922A1 publication Critical patent/AR021922A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C66/00—General aspects of processes or apparatus for joining preformed parts
    • B29C66/70—General aspects of processes or apparatus for joining preformed parts characterised by the composition, physical properties or the structure of the material of the parts to be joined; Joining with non-plastics material
    • B29C66/71—General aspects of processes or apparatus for joining preformed parts characterised by the composition, physical properties or the structure of the material of the parts to be joined; Joining with non-plastics material characterised by the composition of the plastics material of the parts to be joined

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee una formulacion en solucion en aerosol adaptada para ser utilizada en un aerosol presurizado. La formulacion en aerosol se prepara a partir deuna composicion que contiene Budesonido, formoterol, al menos un propelente fluoroalcano, y un cosolvente presente en una cantidad que disuelve o solubilizadichos Budesonido y Formoterol en la mezcla de cosolvente y propelente.
ARP990106573A 1998-12-18 1999-12-20 Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol. AR021922A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/215,280 US6004537A (en) 1998-12-18 1998-12-18 Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol

Publications (1)

Publication Number Publication Date
AR021922A1 true AR021922A1 (es) 2002-09-04

Family

ID=22802357

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106573A AR021922A1 (es) 1998-12-18 1999-12-20 Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.

Country Status (12)

Country Link
US (1) US6004537A (es)
EP (1) EP1140059A2 (es)
JP (1) JP4921639B2 (es)
AR (1) AR021922A1 (es)
AU (1) AU776257B2 (es)
BR (1) BR9916829A (es)
CA (1) CA2355932C (es)
CZ (1) CZ20012216A3 (es)
HU (1) HUP0200014A3 (es)
PL (1) PL348809A1 (es)
TW (1) TW574038B (es)
WO (1) WO2000035441A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
DK0835098T3 (da) * 1995-06-27 2002-10-07 Boehringer Ingelheim Pharma Stabilt lægemiddelpræparat til frembringlese af drivgasfrie aerosoler
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317904B1 (it) * 1999-09-11 2003-07-15 Glaxo Group Ltd Formulazione farmaceutica di propionato di fluticasone.
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
WO2003074024A1 (en) * 2002-03-01 2003-09-12 Chiesi Farmaceutici S.P.A Formoterol superfine formulation
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
PT1542904E (pt) * 2002-08-27 2008-03-24 Schering Corp Processo para produzir formulações para inaladores doseadores
SE0203376D0 (sv) * 2002-11-15 2002-11-15 Astrazeneca Ab New process
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
TWI558685B (zh) * 2005-06-24 2016-11-21 哈尼威爾國際公司 含有經氟取代之烯烴之組合物
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
EP2117504A1 (en) * 2007-02-09 2009-11-18 Schering Corporation Stable pharmaceutical drug aerosols
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2009134524A2 (en) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
JP5873013B2 (ja) 2009-05-29 2016-03-01 パール セラピューティクス，インコーポレイテッド ２つ以上の活性剤を呼吸器送達するための組成物、方法および系
EP2512438B1 (en) 2009-12-16 2017-01-25 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
KR102277635B1 (ko) 2016-09-19 2021-07-19 멕시켐 플루어 소시에다드 아노니마 데 카피탈 바리아블레 약제학적 조성물
JP7268965B2 (ja) * 2018-06-05 2023-05-08 アース製薬株式会社 定量噴射型エアゾール製品および消臭方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
CA2094266C (en) * 1990-10-18 1999-06-01 Robert K. Schultz Aerosol formulations of beclomethasone-17,21-dipropionate
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
WO1992022286A1 (en) * 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
ATE213946T1 (de) * 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
ATE137666T1 (de) * 1991-12-31 1996-05-15 Hoechst Ag Medizinische aerosolformulierung
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use

Also Published As

Publication number Publication date
CA2355932C (en) 2009-06-23
BR9916829A (pt) 2001-10-23
PL348809A1 (en) 2002-06-17
EP1140059A2 (en) 2001-10-10
WO2000035441A2 (en) 2000-06-22
CZ20012216A3 (cs) 2002-04-17
JP2002532418A (ja) 2002-10-02
HUP0200014A3 (en) 2005-06-28
US6004537A (en) 1999-12-21
AU2194900A (en) 2000-07-03
AU776257B2 (en) 2004-09-02
CA2355932A1 (en) 2000-06-22
TW574038B (en) 2004-02-01
HUP0200014A2 (hu) 2002-06-29
WO2000035441A3 (en) 2000-10-26
JP4921639B2 (ja) 2012-04-25

Similar Documents

Publication Publication Date Title
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
ATE254450T1 (de) Aerosolzusammensetzungen
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
BR9913154A (pt) Composição de musse
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
DK1140019T3 (da) Aerosolformulering til baccal og pulmonar anvendelse
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
MY119074A (en) Pharmaceutical aerosol composition
AR036358A1 (es) Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
PT90764A (pt) Processo para a preparacaode um produto farmaceutico compreendendo um estrogenio e um anti-estrigenio e de composicoes farmaceuticas que os contem
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
ES2099649T3 (es) Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida.
ATE173624T1 (de) Synergistische pharmazeutische zusammensetungen, die triamcinolonacetonid und halcinonid enthalten
GEP20032942B (en) Stabile Pharmaceutical Compositions Comprising Levosimendan and Alginic Acid
GR1002731B (el) Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
DK0768896T3 (da) Lavdoserede steroidtabletter, der indeholder gallussyreestere som antioxidant, fremgangsmåde til fremstilling og anvendelse
JPS5762221A (en) Embrocation for external use
JPS5423131A (en) Pharmaceutical composition containing acetylsalicylic acid and ethenzamide
KR960021036A (ko) 콜치신을 유효성분으로 함유하는 항간독성 조성물 및 그 제조방법
ATE140623T1 (de) Pharmazeutische zusammensetzungen für die orale, kutane und intravaginale anwendung in form eines schaums
HUP0300753A2 (hu) Szteroid hormonokat mint transzfer anyagokat tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FC Refusal